Due to tensions in the Middle East, concerns have emerged that the supply of medicines in Pakistan may be affected, while the Drug Regulatory Authority of Pakistan (DRAP) has issued an advisory in view of a possible disruption in the global supply of medicines.
In the issued advisory, pharmaceutical companies have been instructed to maintain an adequate buffer stock of raw materials and finished medicines and to provide medicines to government institutions on a priority basis. In addition, in view of the possible disruption in the global supply of medicines, pharmaceutical companies have been advised to reduce reliance on a single supplier for raw materials.
According to DRAP, companies should adopt multiple sources for raw materials and packing material for medicines so that supply is not affected in any unexpected situation. The advisory instructs pharmaceutical companies to maintain an adequate buffer stock of raw materials and finished medicines and to keep additional reserves to deal with shipping delays or other unforeseen circumstances.
DRAP has also instructed companies to review obstacles in the supply chain and make alternative planning. According to the advisory, effective monitoring of the movement of medicinal products should be carried out and demand should be accurately estimated so that the availability of medicines in the country can be maintained.
DRAP has clarified that effective monitoring will be ensured to prevent hoarding, black marketing and artificial shortages. In addition, pharmaceutical companies have also been instructed to continue supplying medicines to government institutions on a priority basis and to ensure full compliance with the directives of the federal and provincial governments.
